Piper Sandler Reaffirms “Overweight” Rating for Alpha Tau Medical (NASDAQ:DRTS)

Piper Sandler restated their overweight rating on shares of Alpha Tau Medical (NASDAQ:DRTS) in a research note issued to investors on Thursday morning, Benzinga reports. They currently have a $7.00 price objective on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $9.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, June 26th.

Alpha Tau Medical Trading Down 3.1 %

NASDAQ:DRTS opened at $2.18 on Thursday. The company has a quick ratio of 11.60, a current ratio of 11.60 and a debt-to-equity ratio of 0.07. Alpha Tau Medical has a 52-week low of $1.75 and a 52-week high of $4.25. The stock’s 50 day moving average price is $2.18 and its 200 day moving average price is $2.59. The company has a market capitalization of $151.88 million, a PE ratio of -5.32 and a beta of 0.75.

Alpha Tau Medical (NASDAQ:DRTS) last issued its quarterly earnings results on Monday, May 20th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. On average, research analysts anticipate that Alpha Tau Medical will post -0.5 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. USAdvisors Wealth Management LLC acquired a new position in Alpha Tau Medical during the 1st quarter worth approximately $30,000. Aptus Capital Advisors LLC grew its holdings in Alpha Tau Medical by 83.7% during the second quarter. Aptus Capital Advisors LLC now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares during the period. Financial Guidance Group Inc. raised its position in Alpha Tau Medical by 83.7% in the second quarter. Financial Guidance Group Inc. now owns 21,945 shares of the company’s stock worth $56,000 after acquiring an additional 10,000 shares in the last quarter. Caprock Group LLC acquired a new stake in Alpha Tau Medical in the second quarter valued at $59,000. Finally, Telemus Capital LLC purchased a new stake in shares of Alpha Tau Medical during the 4th quarter worth $89,000. 2.65% of the stock is owned by hedge funds and other institutional investors.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.